Effect of prothrombin Belgrade mutation, causing antithrombin resistance, on fibrin clot properties
© 2023 John Wiley & Sons Ltd..
INTRODUCTION: Prothrombin Belgrade mutation is the result of the c.1787G>A substitution in the prothrombin gene. It is located in the antithrombin and sodium binding site and leads to impaired inactivation of thrombin by antithrombin, resulting in antithrombin resistance and thrombotic disorders. However, it negatively affects sodium binding and may have hypocoagulant effects. Considering that prothrombin Belgrade mutation mechanism is still not fully elucidated and that sodium binding is important for thrombin affinity towards fibrinogen, our aim was to determine whether this mutation affects fibrin clot formation and lysis.
METHODS: Using HEK293T cell line, recombinant wild type and mutated prothrombin were generated by transient transfection. Samples that correspond to plasma of a non-carrier, heterozygous and homozygous carriers were reconstituted using prothrombin deficient plasma and recombinant proteins. Reconstituted samples were used in OHP assay (Overall Hemostasis Potential) to determine kinetic profiles of coagulation and fibrinolysis. Clot turbidity assay was performed to observe kinetics of clot formation and lysis more closely. Fibrin clots formed in reconstituted plasma samples were analyzed by confocal microscopy to determine density of fibrin network. Fibrin clots were additionally observed using electron microscopy to determine thickness of individual fibrin fibers.
RESULTS: No significant difference found in OHP, OCP, OFP, and fibrin network density between wild type, heterozygous, and homozygous carrier reconstituted plasma samples. There were significant differences between samples for slope and slope time parameters in kinetic profiles and fibrin fiber thickness.
CONCLUSIONS: Results indicate that prothrombin Belgrade mutation has no significant impact on fibrinolysis, however it may affect kinetics of clot formation and its architecture.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
International journal of laboratory hematology - 46(2024), 2 vom: 07. März, Seite 329-335 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dunjic Manevski, Sofija [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9000-94-6 |
|---|
| Anmerkungen: |
Date Completed 20.03.2024 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ijlh.14195 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364108436 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364108436 | ||
| 003 | DE-627 | ||
| 005 | 20240320233615.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ijlh.14195 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM364108436 | ||
| 035 | |a (NLM)37918971 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dunjic Manevski, Sofija |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of prothrombin Belgrade mutation, causing antithrombin resistance, on fibrin clot properties |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2024 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons Ltd. | ||
| 520 | |a INTRODUCTION: Prothrombin Belgrade mutation is the result of the c.1787G>A substitution in the prothrombin gene. It is located in the antithrombin and sodium binding site and leads to impaired inactivation of thrombin by antithrombin, resulting in antithrombin resistance and thrombotic disorders. However, it negatively affects sodium binding and may have hypocoagulant effects. Considering that prothrombin Belgrade mutation mechanism is still not fully elucidated and that sodium binding is important for thrombin affinity towards fibrinogen, our aim was to determine whether this mutation affects fibrin clot formation and lysis | ||
| 520 | |a METHODS: Using HEK293T cell line, recombinant wild type and mutated prothrombin were generated by transient transfection. Samples that correspond to plasma of a non-carrier, heterozygous and homozygous carriers were reconstituted using prothrombin deficient plasma and recombinant proteins. Reconstituted samples were used in OHP assay (Overall Hemostasis Potential) to determine kinetic profiles of coagulation and fibrinolysis. Clot turbidity assay was performed to observe kinetics of clot formation and lysis more closely. Fibrin clots formed in reconstituted plasma samples were analyzed by confocal microscopy to determine density of fibrin network. Fibrin clots were additionally observed using electron microscopy to determine thickness of individual fibrin fibers | ||
| 520 | |a RESULTS: No significant difference found in OHP, OCP, OFP, and fibrin network density between wild type, heterozygous, and homozygous carrier reconstituted plasma samples. There were significant differences between samples for slope and slope time parameters in kinetic profiles and fibrin fiber thickness | ||
| 520 | |a CONCLUSIONS: Results indicate that prothrombin Belgrade mutation has no significant impact on fibrinolysis, however it may affect kinetics of clot formation and its architecture | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a fibrin | |
| 650 | 4 | |a microscopy | |
| 650 | 4 | |a mutation | |
| 650 | 4 | |a prothrombin | |
| 650 | 4 | |a thrombosis | |
| 650 | 7 | |a Fibrin |2 NLM | |
| 650 | 7 | |a 9001-31-4 |2 NLM | |
| 650 | 7 | |a Prothrombin |2 NLM | |
| 650 | 7 | |a 9001-26-7 |2 NLM | |
| 650 | 7 | |a Antithrombins |2 NLM | |
| 650 | 7 | |a Thrombin |2 NLM | |
| 650 | 7 | |a EC 3.4.21.5 |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Antithrombin III |2 NLM | |
| 650 | 7 | |a 9000-94-6 |2 NLM | |
| 650 | 7 | |a Sodium |2 NLM | |
| 650 | 7 | |a 9NEZ333N27 |2 NLM | |
| 700 | 1 | |a Cumbo, Marija |e verfasserin |4 aut | |
| 700 | 1 | |a Pruner, Iva |e verfasserin |4 aut | |
| 700 | 1 | |a Gvozdenov, Maja |e verfasserin |4 aut | |
| 700 | 1 | |a Tomic, Branko |e verfasserin |4 aut | |
| 700 | 1 | |a Taxiarchis, Apostolos |e verfasserin |4 aut | |
| 700 | 1 | |a Antovic, Jovan |e verfasserin |4 aut | |
| 700 | 1 | |a Djordjevic, Valentina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of laboratory hematology |d 2007 |g 46(2024), 2 vom: 07. März, Seite 329-335 |w (DE-627)NLM167703048 |x 1751-553X |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2024 |g number:2 |g day:07 |g month:03 |g pages:329-335 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ijlh.14195 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2024 |e 2 |b 07 |c 03 |h 329-335 | ||